Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Miner

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Alimentary Pharmacology & Therapeutics|February 12, 2010
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitorsP B Miner, L A McKean, R D Gibb, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2000
Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trialN J Talley, M Verlinden, W Snape, et al.
Gastroenterology|June 26, 1999
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's diseaseB E Sands, S Bank, C A Sninsky, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Alimentary Pharmacology & Therapeutics|February 12, 2010
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitorsP B Miner, L A McKean, R D Gibb, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2000
Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trialN J Talley, M Verlinden, W Snape, et al.
Gastroenterology|June 26, 1999
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's diseaseB E Sands, S Bank, C A Sninsky, et al.
Pageof 8